Patents by Inventor Gary J. Bridger

Gary J. Bridger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination Therapy
    Publication number: 20100003224
    Abstract: Methods to mobilize progenitor and/or stem cells from the bone marrow to the bloodstream by administering a combination of at least one CXCR4 inhibitor and at least one VLA-4 inhibitor are described. The combinations may also be used to treat multiple myeloma.
    Type: Application
    Filed: August 2, 2007
    Publication date: January 7, 2010
    Applicant: GENZYME CORPORATION
    Inventors: Gary J. Bridger, Louis M. Pelus
  • Chemokine receptor binding heterocyclic compounds
    Patent number: 7629337
    Abstract: Heterocyclic compounds that bind chemokine receptors and inhibit the binding of their natural ligands are disclosed. The invention compounds are protective against infection by HIV and exert effects characteristic of antagonists to the CXCR4 receptor.
    Type: Grant
    Filed: July 27, 2006
    Date of Patent: December 8, 2009
    Assignee: Genzyme Corporation
    Inventors: Gary J. Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols
  • CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY
    Publication number: 20090281308
    Abstract: Compounds that interact with the CXCR4 receptor are described. These compounds are useful in treating, for Example, HIV infection and inflammatory conditions such as rheumatoid arthritis, as well as asthma or cancer, and are useful in methods to elevate progenitor and stem cell counts as well as methods to elevate white blood cell counts.
    Type: Application
    Filed: May 15, 2009
    Publication date: November 12, 2009
    Inventors: Gary J. BRIDGER, Ernest J. MCEACHERN, Renato SKERLJ, Dominique SCHOLS, Ian BAIRD, Al KALLER, Curtis HARWIG, Yongbao ZHU, Gang CHEN, Krystyna SKUPINSKA, Markus METZ
  • Chemokine receptor binding heterocyclic compounds with enhanced efficacy
    Patent number: 7550484
    Abstract: Compounds that interact with the CXCR4 receptor are described. These compounds are useful in treating, for Example, HIV infection and inflammatory conditions such as rheumatoid arthritis, as well as asthma or cancer, and are useful in methods to elevate progenitor and stem cell counts as well as methods to elevate white blood cell counts.
    Type: Grant
    Filed: April 22, 2004
    Date of Patent: June 23, 2009
    Assignee: Genzyme Corporation
    Inventors: Gary J. Bridger, Ernest J. McEachern, Renato Skerlj, Dominique Schols, Ian Baird, Al Kaller, Curtis Harwig, Yongbao Zhu, Gang Chen, Krystyna Skupinska, Markus Metz
  • Chemokine receptor binding compounds
    Patent number: 7498346
    Abstract: The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    Type: Grant
    Filed: June 14, 2005
    Date of Patent: March 3, 2009
    Assignee: Genzyme Corporation
    Inventors: Yuanxi Zhou, Gary J. Bridger, Renato T. Skerlj, David Bogucki, Wen Yang, Elyse Bourque, Jonathan Langille, Tong-Shuang Li, Markus Metz
  • Chemokine receptor binding compounds
    Patent number: 7491735
    Abstract: The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: February 17, 2009
    Assignee: Genzyme Corporation
    Inventors: Yuanxi Zhou, Gary J. Bridger, Renato T. Skerlj, David Bogucki, Wen Yang, Elyse Bourque, Jonathan Langille, Tong-Shuang Li, Markus Metz, Maria R. Di Fluri, Siqiao Nan
  • CXCR4 ANTAGONISTS
    Publication number: 20080287454
    Abstract: The present invention is drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV- or FIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors that mediate a number of mammalian embryonic developmental processes.
    Type: Application
    Filed: July 29, 2008
    Publication date: November 20, 2008
    Inventors: Gary J. BRIDGER, Eva Maria BOEHRINGER, Zhongren WANG, Dominique SCHOLS, Renato Tony SKERLJ, David Earl BOGUCKI
  • Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
    Patent number: 7452994
    Abstract: This invention describes various processes for synthesis and resolution of racemic amino-substituted fused bicyclic ring systems. One process utilizes selective hydrogenation of an amino-substituted fused bicyclic aromatic ring system. An alternative process prepares the racemic amino-substituted fused bicyclic ring system via nitrosation. In addition, the present invention describes the enzymatic resolution of a racemic mixture to produce the (R)- and (S)-forms of amino-substituted fused bicyclic rings as well as a racemization process to recycle the unpreferred enantioner. Further provided by this invention is an asymmetric synthesis of the (R)- or (S)-enantiomer of primary amino-substituted fused bicyclic ring systems.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: November 18, 2008
    Assignee: Anormed, Inc.
    Inventors: Ernest J. McEachern, Gary J. Bridger, Krystyna A. Skupinska, Renato T. Skerlj, Wen Yang
  • CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS
    Publication number: 20080255197
    Abstract: The present invention relates to compounds that bind to chemokine receptors, and having the formula wherein each A, X, Y, R1, R2 and R3 are substituents. The present invention also relates to methods of using such compounds, such as in treating HIV infection and inflammatory conditions such as rheumatoid arthritis. Furthermore, the present invention relates to methods to elevate progenitor and stem cell counts, as well as methods to elevate white blood cell counts, using such compounds.
    Type: Application
    Filed: November 6, 2007
    Publication date: October 16, 2008
    Inventors: Gary J. BRIDGER, Ernest J. McEachern, Renato Skerlj, Dominique Schols, Ian Baird, Al Kaller, Curtis Harwig, Yongbao Zhu, Gang Chen, Krystyna Skupinska
  • Methods to modulate conditions mediated by the CXCR4 receptor
    Patent number: 7414065
    Abstract: The present invention is drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV- or FIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors that mediate a number of mammalian embryonic developmental processes.
    Type: Grant
    Filed: November 17, 2004
    Date of Patent: August 19, 2008
    Assignee: Genzyme Corporation
    Inventors: Gary J. Bridger, Eva Maria Boehringer, Zhongren Wang, Dominique Schols, Renato Tony Skerlj, David Earl Bogucki
  • Chemokine receptor binding heterocyclic compounds with enhanced efficacy
    Patent number: 7354934
    Abstract: The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    Type: Grant
    Filed: December 13, 2005
    Date of Patent: April 8, 2008
    Assignee: Anormed, Inc.
    Inventors: Gary J. Bridger, Al Kaller, Curtis Harwig, Renato T. Skerlj, David Bogucki, Trevor R. Wilson, Jason B. Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis Smith, Maria R. Di Fluri
  • CXCR4 chemokine receptor binding compounds
    Patent number: 7291631
    Abstract: The present invention relates to compounds that bind to chemokine receptors, and having the formula wherein each A, X, Y, R1, R2 and R3 are substituents. The present invention also relates to methods of using such compounds, such as in treating HIV infection and inflammatory conditions such as rheumatoid arthritis. Furthermore, the present invention relates to methods to elevate progenitor and stem cell counts, as well as methods to elevate white blood cell counts, using such compounds.
    Type: Grant
    Filed: April 12, 2004
    Date of Patent: November 6, 2007
    Assignee: Genzyme Corporation
    Inventors: Gary J. Bridger, Ernest J. McEachern, Renato Skerlj, Dominique Schols, Ian Baird, Al Kaller, Curtis Harwig, Yongbao Zhu, Gang Chen, Krystyna Skupinska
  • Use of rare earth compounds for the prevention of kidney stone disease
    Patent number: 7192609
    Abstract: Conditions such as kidney stones, which are characterized by undesired absorption of oxalate from the intestinal tract are conveniently treated using nontoxic salts of rare earth metal ions.
    Type: Grant
    Filed: April 22, 2002
    Date of Patent: March 20, 2007
    Assignee: Shire International Licensing B.V.
    Inventors: Michael J. Abrams, Gary J. Bridger, Simon P. Fricker, Stefan R. Idzan
  • Chemokine receptor binding heterocyclic compounds
    Patent number: 7183273
    Abstract: Heterocyclic compounds that bind chemokine receptors and inhibit the binding of their natural ligands are disclosed. The invention compounds are protective against infection by HIV and exert effects characteristic of antagonists to the CXCR4 receptor.
    Type: Grant
    Filed: April 30, 2004
    Date of Patent: February 27, 2007
    Assignee: AnorMED, Inc.
    Inventors: Gary J. Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols
  • Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
    Patent number: 7135570
    Abstract: This invention describes various processes for synthesis and resolution of racemic amino-substituted fused bicyclic ring systems. One process utilizes selective hydrogenation of an amino-substituted fused bicyclic aromatic ring system. An alternative process prepares the racemic amino-substituted fused bicyclic ring system via nitrosation. In addition, the present invention describes the enzymatic resolution of a racemic mixture to produce the (R)— and (S)— forms of amino-substituted fused bicyclic rings as well as a racemization process to recycle the unpreferred enantioner. Further provided by this invention is an asymmetric synthesis of the (R)— or (S)— enantiomer of primary amino-substituted fused bicyclic ring systems.
    Type: Grant
    Filed: October 6, 2004
    Date of Patent: November 14, 2006
    Assignee: Anormed Inc.
    Inventors: Ernest J. McEachern, Gary J. Bridger, Krystyna A. Skupinska, Renato T. Skerlj, Wen Yang
  • Methods to mobilize progenitor/stem cells
    Patent number: 6987102
    Abstract: Certain nitrogen-containing compounds that bind the chemokine receptor CXCR4 are able to mobilize progenitor and/or stem cells into the peripheral blood to permit harvesting them for stem cell transplantation.
    Type: Grant
    Filed: July 30, 2002
    Date of Patent: January 17, 2006
    Assignee: Anormed, Inc.
    Inventors: Gary J. Bridger, Michael J. Abrams, Geoffrey W. Henson, Ronald Trevor MacFarland, Gary B. Calandra, Hal E. Broxmeyer, David C. Dale
  • Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
    Patent number: 6825351
    Abstract: This invention describes various processes for synthesis and resolution of racemic amino-substituted fused bicyclic ring systems. One process utilizes selective hydrogenation of an amino-substituted fused bicyclic aromatic ring system. An alternative process prepares the racemic amino-substituted fused bicyclic ring system via nitrosation. In addition, the present invention describes the enzymatic resolution of a racemic mixture to produce the (R)- and (S)-forms of amino-substituted fused bicyclic rings as well as a racemization process to recycle the unpreferred enantioner. Further provided by this invention is an asymmetric synthesis of the (R)- or (S)-enantiomer of primary amino-substituted fused bicyclic ring systems.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: November 30, 2004
    Assignee: Anormed, Inc.
    Inventors: Ernest J. McEachern, Gary J. Bridger, Krystyna Skupinska, Renato T. Skerlj
  • Chemokine receptor binding heterocyclic compounds
    Publication number: 20040235823
    Abstract: This invention relates to a novel class of heterocyclic compounds that bind chemokine receptors, inhibiting the binding of their natural ligands thereby. These compounds result in protective effects against infection by HIV through binding to chemokine receptors, including CXCR4 and CCR5, thus inhibiting the subsequent binding by these chemokines.
    Type: Application
    Filed: April 30, 2004
    Publication date: November 25, 2004
    Inventors: Gary J. Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols
  • Methods to mobilize progenitor/stem cells
    Publication number: 20030130250
    Abstract: Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed.
    Type: Application
    Filed: July 30, 2002
    Publication date: July 10, 2003
    Inventors: Gary J. Bridger, Michael J. Abrams, Geoffrey W. Henson, Ronald Trevor MacFarland, Gary B. Calandra
  • Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
    Publication number: 20030114679
    Abstract: This invention describes various processes for synthesis and resolution of racemic amino-substituted fused bicyclic ring systems. One process utilizes selective hydrogenation of an amino-substituted fused bicyclic aromatic ring system. An alternative process prepares the racemic amino-substituted fused bicyclic ring system via nitrosation. In addition, the present invention describes the enzymatic resolution of a racemic mixture to produce the (R)- and (S)-forms of amino-substituted fused bicyclic rings as well as a racemization process to recycle the unpreferred enantioner. Further provided by this invention is an asymmetric synthesis of the (R)- or (S)-enantiomer of primary amino-substituted fused bicyclic ring systems.
    Type: Application
    Filed: September 12, 2002
    Publication date: June 19, 2003
    Inventors: Ernest J. McEachern, Gary J. Bridger, Krystyna A. Skupinska, Renato T. Skerlj